Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
First filed May 2016, updated Aug. 2020 - Completed
CATEGORIES: Lupus Nephritis
The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the dose-response relationship within the therapeutic range, and select the target dose for phase III development.
Study sponsor: Boehringer Ingelheim
To Learn More Contact
Boehringer Ingelheim Call Center at1-800-243-0127 or firstname.lastname@example.org
ClinicalTrials.gov identifier: NCT02770170